Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Imac Holdings ( (BACK) ) is now available.
On September 10, 2025, Ignite Proteomics announced a collaboration with Inova Health to conduct a biomarker study using RPPA technology on tumor samples from late-stage gastrointestinal cancer patients. This partnership aims to provide oncologists with actionable data to guide treatment decisions where current guidance is lacking, potentially enhancing precision medicine approaches. The collaboration is significant for Ignite Proteomics, expected to contribute meaningfully to its 2025 revenue, and highlights the expanding applications of RPPA technology in solid tumors.
Spark’s Take on BACK Stock
According to Spark, TipRanks’ AI Analyst, BACK is a Underperform.
IMAC Holdings has a low overall stock score due to significant financial challenges, negative valuation metrics, and technical indicators suggesting weak momentum. The risk of Nasdaq delisting further exacerbates the company’s precarious position. The lack of earnings call data limits further insights into potential strategic actions or improvements.
To see Spark’s full report on BACK stock, click here.
More about Imac Holdings
Ignite Proteomics, a subsidiary of IMAC Holdings, operates in the precision oncology industry, providing pathway-level protein analytics to guide treatment decisions. The company runs a CLIA-certified, CAP-accredited laboratory and utilizes its clinical Reverse Phase Protein Array (RPPA) assay to quantify protein biomarkers, aiding oncologists and drug developers in matching patients with effective therapies.
Average Trading Volume: 15,883
Technical Sentiment Signal: Sell
Current Market Cap: $272.5K
Find detailed analytics on BACK stock on TipRanks’ Stock Analysis page.